Carmichael John D
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Patient Prefer Adherence. 2012;6:73-82. doi: 10.2147/PPA.S20783. Epub 2012 Jan 18.
Acromegaly is a rare disease characterized by excessive growth hormone secretion, usually from a pituitary tumor. Treatment options include surgery, medical therapy, and in some cases, radiation therapy. Current medical therapy consists of treatment with somatostatin analog medications or a growth hormone receptor antagonist. There are two somatostatin analogs currently in use, octreotide and lanreotide. Both are supplied in long-acting formulations and are of comparable biochemical efficacy. Lanreotide is supplied in a prefilled syringe and is injected into deep subcutaneous tissue. Studies have been conducted to assess the efficacy of self- or partner administration, and have demonstrated that injection of lanreotide can be accomplished reliably and safely outside a physician's office. For patients who have achieved biochemical control with lanreotide, the FDA has recently approved an extended dosing interval. Selected patients may be able to receive the medication less frequently with injections of 120 mg administered every 6 or 8 weeks. This review focuses on the use of lanreotide in the treatment of acromegaly, the safety and efficacy of the drug, and the benefits afforded to patients because of unique aspects of the delivery of lanreotide.
肢端肥大症是一种罕见疾病，其特征为生长激素分泌过多，通常源于垂体肿瘤。治疗选择包括手术、药物治疗，某些情况下还包括放射治疗。目前的药物治疗包括使用生长抑素类似物药物或生长激素受体拮抗剂。目前正在使用的生长抑素类似物有两种，即奥曲肽和兰瑞肽。两者均有长效制剂供应，且生化疗效相当。兰瑞肽以预填充注射器形式提供，注入深部皮下组织。已经开展了研究以评估自我给药或由伴侣给药的疗效，结果表明在医生办公室以外也能够可靠且安全地注射兰瑞肽。对于使用兰瑞肽已实现生化控制的患者，美国食品药品监督管理局（FDA）最近批准了延长给药间隔。部分患者每6或8周注射120 mg药物，可能能够减少用药频率。本综述重点关注兰瑞肽在肢端肥大症治疗中的应用、药物的安全性和疗效，以及因兰瑞肽给药方式的独特之处而带给患者的益处。
